Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 229Leukemia, Lymphocytic, Chronic, B-Cell 213Leukemia 203Myelodysplastic Syndromes 182Precursor Cell Lymphoblastic Leukemia-Lymphoma 174Lymphoma, Non-Hodgkin 121Lymphoma 120Hodgkin Disease 108Multiple Myeloma 107Lymphoma, Follicular 100Lymphoma, Mantle-Cell 99Lymphoma, Large B-Cell, Diffuse 86Lymphoma, B-Cell, Marginal Zone 85Congenital Abnormalities 85Myeloproliferative Disorders 84Burkitt Lymphoma 81Leukemia, Myelomonocytic, Chronic 77Leukemia, Myelogenous, Chronic, BCR-ABL Positive 75Leukemia, Myeloid, Chronic-Phase 74Leukemia, Myeloid, Accelerated Phase 73Lymphoma, Large-Cell, Immunoblastic 61Anemia, Refractory, with Excess of Blasts 60Blast Crisis 55Primary Myelofibrosis 53Waldenstrom Macroglobulinemia 52Neoplasms, Plasma Cell 52Recurrence 48Hematologic Neoplasms 45Dendritic Cell Sarcoma, Interdigitating 42Leukemia, Prolymphocytic 41

Interventions

siltuximab 1fludarabine phosphate 1fludarabine 1Metoprolol 1Infliximab 1Etanercept 1Cyclophosphamide 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytokine Release Syndrome × fludarabine phosphate × Other hematologic neoplasm × Clear all
NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Active not recruiting
17 enrolled
LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡